Cargando…

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma

Rationale. The diagnosis of pleural malignant mesothelioma (MM) by effusion cytology may be difficult and is currently controversial. Effusion mesothelin levels are increased in patients with MM but the clinical role of this test is uncertain. Objectives. To determine the clinical value of measuring...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creaney, Jenette, Segal, Amanda, Olsen, Nola, Dick, Ian M., Musk, A. W(Bill), Skates, Steven J., Robinson, Bruce W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258360/ https://www.ncbi.nlm.nih.gov/pubmed/25505814 http://dx.doi.org/10.1155/2014/413946

Ejemplares similares

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
por: Birnie, Kimberly A., et al.
Publicado: (2019)

Hyaluronic acid in viscous malignant mesothelioma pleural effusion
por: Cheah, Hui Min, et al.
Publicado: (2020)

Discovery of new biomarkers for malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2015)

Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance
por: Popowicz, Natalia, et al.
Publicado: (2021)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma
por: Choi, Agnes Y., et al.
Publicado: (2022)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Auto-Antibodies to β-F1-ATPase and Vimentin in Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2011)

Profile of soluble factors in pleural effusions predict prognosis in mesothelioma
por: Dick, I.M., et al.
Publicado: (2022)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Fluid-to-Blood BNP Ratio May Contribute to Prognosis in Malignant Pleural Mesothelioma
por: Tsolaki, Vasiliki, et al.
Publicado: (2023)

Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
por: Chee, Jonathan, et al.
Publicado: (2018)

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma
por: Qualiotto, Aline Nery, et al.
Publicado: (2023)

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
por: Greening, David W., et al.
Publicado: (2016)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2022)

MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2014)

Genetic Variants Associated with Increased Risk of Malignant Pleural Mesothelioma: A Genome-Wide Association Study
por: Matullo, Giuseppe, et al.
Publicado: (2013)

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
por: Eguchi, Takashi, et al.
Publicado: (2017)

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2013)

Correction: Genetic Variants Associated with Increased Risk of Malignant Pleural Mesothelioma: A Genome-Wide Association Study
por: Matullo, Giuseppe, et al.
Publicado: (2015)

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2017)

Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma
por: Muruganandan, Sanjeevan, et al.
Publicado: (2017)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_khb4l37sr87muj6ff33u6mm2qo